Objective: To describe the pharmacokinetics of atazanavir (ATV) and ritonavir-boosted ATV (ATV/r) in children aged 91 days to 21 years.
Introduction
In 2009, 2.5 million children worldwide were estimated to be living with HIV infection, 90% of whom reside in Africa [1] . Although HIV-related deaths in children and the incidence of mother-to-child transmission of HIV have declined globally, rates are still unacceptably high in some resource-limited countries [2, 3] . Additionally, many children infected with HIV at birth in high-resource countries have aged into adolescence and adulthood. Many of these children and young adults are highly treatment-experienced and developing long-term toxicities associated with current antiretroviral drugs and are, therefore, in need of new treatment options [4] . Unfortunately, not all of the antiretroviral agents deemed well tolerated and efficacious in HIV-infected adults are approved for use in children or available in pediatric formulations. Thus, additional antiretroviral options and formulations are needed for use in children.
Atazanavir (ATV), an azapeptide HIV protease inhibitor, is administered once daily as part of combination antiretroviral therapy. The Food and Drug Administration (FDA)-approved dosing in adults is 300 mg ATVonce daily when administered with ritonavir as a pharmacokinetic enhancer, and 400 mg ATV once daily in the absence of ritonavir. ATV and ATV boosted with ritonavir (ATV/r) have demonstrated excellent virologic efficacy with favorable tolerability in several pivotal clinical trials in adults [5] [6] [7] [8] . Relative to other protease inhibitors, ATV causes fewer perturbations in lipids and less gastrointestinal intolerance. The most common toxicity of ATV is asymptomatic accumulation of indirect bilirubin due to inhibition of uridine glucuronosyl transferase 1A1, which results in cosmetic effects (e.g., jaundice, scleral icterus) in 5-9% of adult patients.
ATV is primarily metabolized by cytochrome P450 (CYP450) 3A and also inhibits this hepatic enzyme. ATV concentrations are increased with food and, thus, the drug should be administered with a meal. ATV absorption is pH-dependent and concomitant administration of gastric acid modifiers should be avoided.
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1020A was a phase I/II open-label study to evaluate the safety and pharmacokinetics, and to determine the appropriate doses, of ATV and ATV/r as part of combination antiretroviral therapy in antiretroviral treatment-naive and treatment-experienced HIV-infected infants, children, and adolescents from the United States and South Africa. Two formulations of ATV, capsules and a dispersible orange-vanilla flavored powder, were evaluated. This manuscript presents the pharmacokinetic findings of the study.
Methods

Patients
HIV-infected treatment-naive and treatment-experienced children 91 days to 21 years of age with plasma HIV-1 RNA levels higher than 5000 copies/ml were eligible to receive ATV or ATV/r with two nucleoside reverse transcriptase inhibitors (NRTIs) (excluding abacavir and tenofovir disoproxil fumarate). Baseline genotypic resistance testing was performed on all antiretroviral-experienced participants and genotypic susceptibility to the NRTIs in their regimen confirmed. Participants previously treated with more than one HIV protease inhibitor had a baseline viral phenotypic assay performed; those with less than 10-fold loss of sensitivity to ATV remained eligible. Participants who were pregnant or breastfeeding, had hepatitis, had any clinical or laboratory event at baseline greater than grade 2 as per the 1994 Division of AIDS (DAIDS) table for grading the severity of pediatric (>3 months) adverse experiences [9] , had cardiac abnormalities, or had received intravenous pentamidine for prophylaxis or treatment of Pneumocytis jiroveci within 3 months of study entry were ineligible. Female participants of reproductive potential were required to use at least two forms of contraception and males engaging in sexual intercourse that could result in pregnancy were required to use condoms. Participants receiving systemic cytotoxic chemotherapy, acetaminophen exceeding 7 days, anabolic steroids, megestrol acetate, interleukins, interferons, thalidomide, verapamil, intravenous pentamidine, and growth hormone were excluded. Consumption of grapefruit juice was prohibited.
Study design
IMPAACT P1020A was a phase I/II, open-label, multicenter study of ATV and ATV/r as part of combination antiretroviral treatment of HIV-infected infants, children, and adolescents. Participants from the United States and South Africa were enrolled. Unboosted ATV and ATV/r were evaluated in several age and formulation groups. These groups are shown in Table 1 . Group assignment was based on age, and the formulation and dose being evaluated at the time of enrollment. The study was originally designed to evaluate doses in at least eight groups, but a ninth group was added to define better the pharmacokinetics and safety of ATV/r in infants aged 3-6 months (group 5A, Table 1 ).
All participants underwent 24-h intensive pharmacokinetic sampling 7 days after starting treatment with ATV or ATV/r, after 56 weeks of treatment, and 14 days after any pharmacokinetic-guided dose adjustment. For these intensive pharmacokinetic visits, participants were admitted approximately 24 h after their previous ATV dose. A light (nonstandardized) meal was consumed. A predose sample was obtained 15-30 min following the meal. Within 30 min of the predose sample, clinic personnel observed study drug(s) administration. Whole blood for quantification of ATV (and ritonavir in those participants taking ritonavir) in plasma was obtained at 1, 2, 3, 4, 6, 8, and 12-h postdose and the following day at 24-h postdose.
Study drug(s)
Atazanavir ATV was supplied as 50, 100, and 200 mg capsules and powder containing 50 mg of ATV in a 2.5 ml scoop. The ATV powder also contained sucrose, aspartame, and an orange-vanilla flavor. The powder could be mixed with applesauce, milk, yogurt, water, or formula within 3 h of dosing. There were limited (unpublished) data on ATV powder bioavailability relative to the capsules in seven adults at the time of study initiation.
Ritonavir
Commercially available ritonavir liquid and capsules were used. Participants with a body surface area (BSA) less than 0.66 m 2 took ritonavir liquid and those weighing at least 0.66 m 2 could take the liquid or capsule formulation. The 80 mg/ml orange liquid could be mixed with chocolate milk, pudding, custards or nutritional supplements within an hour of dosing.
Bioanalyses
Blood for determination of ATV and ritonavir was processed by centrifugation with the plasma stored (À708C) within 30 min of collection. ATV and ritonavir plasma concentrations were determined using a simultaneous, validated HPLC-ultraviolet method. Briefly, after addition of internal standard, a liquid-liquid extraction procedure with t-butylmethylether at basic pH was used to prepare the samples. The chromatographic separation of the compounds and the internal standard was accomplished on a Waters YMC HPLC, 100 Â 4.6 mm, reversed-phase octyl column with a 3 mm particle size (Waters Corp., Milford, Massachusetts, USA). The mobile phase consisted of 54.7% 20 mmol/l acetate buffer/45.3% acetonitrile, pH 4.9 with an isocratic flow rate of 1 ml/min. Detection and quantification of the drugs was at 212 nm. The assay was linear over the range of 20-20 000 ng/ml with a minimum limit of quantification of 20 ng/ml using 0.2 ml of human plasma. The standard curves generated had coefficients of determination (r 2 ) greater than 0.9988. Precision and accuracy were measured in quality controls at 75, 750, and 7500 ng/ml, and all accuracies were within 15% of the nominal concentration with percentage relative SD of less than 10%.
Pharmacokinetic targets
In adults, the geometric mean (%CV) ATV 24-h area under the concentration time curves (AUC 0-24hr ) and concentration 24-h postdose (C 24 ) are 14 874 ng Â h/ml (91) and 120 ng/ml (109), respectively, following a 400-mg unboosted ATV dose, and 46 073 ng Â h/ml (66) and 636 ng/ml (97), respectively, following a 300-mg ATV dose with 100 mg of ritonavir [10] . For this study, the cohort AUC 0-24hr target was 45 000 and 15 000 ng Â h/ml was considered the minimum acceptable AUC 0-24hr . Owing to the faster elimination half-lives observed in young children relative to adults taking protease inhibitors, an AUC 0-24hr of 15 000 ng Â h/ml was expected to correspond to a C 24 of 60 ng/ml (the in-vitro protein-binding adjusted 95% inhibitory concentration [11] ).
Cohort
Allometric scaling indicated an ATV dose of 310 mg/m 2 should provide average exposures of 45 000 ng Â h/ml for a cohort. Thus, all groups were started at this dose. To establish an acceptable ATV or ATV/r dose for a given age range, 10 patients had to meet the a-priori protocol-defined safety and pharmacokinetic criteria. The pharmacokinetic cohort dose acceptance criteria were as follows: ATV AUC 0-24hr of at least 30 000 ng Â h/ml and C 24 of at least 60 ng/ml in at least 80% of patients; no AUC 0-24hr less than 15 000 ng Â h/ml; and median AUC 0-24hr of 60 000 ng Â h/ml or less. Safety criteria were, first, no life threatening toxicities; second, one or fewer patients with grade 3 or 4 toxicities (not including bilirubin) attributable to study treatment; and, third, two or fewer patients with total bilirubin values greater than 5.1 times the upper limit of normal. Cohort dose finding proceeded with the initial enrollment of five participants in a cohort. If pharmacokinetic and safety criteria were not met, the cohort ATV starting dose was modified, either increased to 415, 520 then 620 mg/m 2 or decreased to 205 mg/m 2 , and five new participants were enrolled. If pharmacokinetic and safety criteria were met, five additional patients were enrolled at that dose, and pharmacokinetics re-evaluated for the first 10 study participants treated at this dose.
Individual participant
Each participant's AUC 0-24hr was determined and reported within 2 weeks of an intensive pharmacokinetic visit. Participants with AUC 0-24hr of less than 30 000 ng Â h/ml had their ATV dose increased, and those with AUC 0-24hr of more than 90 000 ng Â h/ml underwent ATV dose decreases. Doses were adjusted to target an individual AUC 0-24hr of 45 000 ng Â h/ml (the cohort AUC 0-24hr target), but no doses were increased by an amount greater than 250 mg at one time in any individual participant. Doses were decreased in the event of a grade 3 or higher toxicity per the DAIDS tables and/or total bilirubin values greater than or equal to 5.1 times the upper limit of normal. Participants with total bilirubin values greater than 10 times the upper limit of normal were discontinued from study. Repeat 24-h pharmacokinetic studies were performed 14 days after these dose adjustments to confirm exposures. Participants with at least 25% increase in weight also underwent dose increases.
Pharmacokinetic assessments
Pharmacokinetics were determined by noncompartmental analysis and AUC 0-24hr calculated by the linear trapezoidal method. Maximum concentration (C max ) and C 24 were determined visually, except in the instance when the patient redosed the study medication prior to the 24-h blood draw or when the 24-h level was not obtained, in which case the C 24 was calculated from the elimination rate (k e ) and the last measured concentration. Apparent oral clearance (C L/F ) was calculated as ATV dose divided by AUC 0-24hr .
Statistical methods
Descriptive statistics were used to summarize demographic and pharmacokinetic data in the individual dosing cohorts. Univariate correlations between age, BSA, and weight vs. ATV AUC 0-24hr at day 7 in the dosing cohorts that satisfied the protocol-defined pharmacokinetic criteria were evaluated using the Pearson correlation coefficient. The following statistical tests were used to evaluate whether the mean ATV AUC 0 -24hr in the dosing cohorts, which satisfied the protocol-defined pharmacokinetic criteria, varied by sex, formulation, country, ritonavir boosting (univariate t-test), or race (analysis of variance F-test). P values less than 0.05 were considered significant. SAS version 9 (SAS Institute Inc., Cary, North Carolina, USA) was used for data analyses.
Results
Participants
One hundred and ninety-five HIV-infected infants, children, and adolescents were enrolled and 172 (51% female) had evaluable pharmacokinetic data at day 7.
Of the 23 participants without evaluable pharmacokinetic data, 10 had problems with adherence; four had dosing errors; sample integrity was compromised for three during shipment from South Africa; two were not sampled at day 7; one did not consent; one inadvertently enrolled; one had problems with intravenous access; and one discontinued due to nausea and vomiting prior to day 7. Sixty-two percent participants received ATV capsules and 38% received ATV powder. Seventy-eight participants (45%) were naive to antiretroviral treatment. The median (range) age, weight, and BSA at the day 7 intensive pharmacokinetic visit were 8.7 years (0.3-21.3), 26.6 kg (4.3-121.9), and 0.98 m 2 (0.27-2.32), respectively. One hundred and ten (64%) and 62 (36%) participants were from the United States and South Africa, respectively. Sixty-five percent were black, 23% were white, and 29% of participants were of Hispanic ethnicity regardless of race. The median (range) HIV viral load, CD4 cell count, and CD4 percentage at entry were 4.7 log 10 copies/ml (3.3-6.5), 459 cells/ml (0-3060), and 19% (0-46), respectively.
Pharmacokinetics
Five dosing cohorts (two unboosted and three ritonavirboosted) satisfied the protocol-defined safety and pharmacokinetic criteria ( Table 2) . Two ritonavirboosted dosing cohorts, group 5 and 5A, which enrolled children of ages 3 months to 2 years, did not satisfy the protocol-defined pharmacokinetic criteria. There was considerable intersubject variability in systemic exposures in this age group, such that a dose escalation to 415 mg/m 2 may have resulted in ATV exposures in some children of greater than 90 000 ng Â h/ml. Thus, a further dose increase in group 5 and 5A was not attempted; however, the parameters for these groups are included in Table 2 and in statistical determinations of predictors of ATV exposures.
The dosing cohorts that failed to meet the protocoldefined pharmacokinetic criteria are shown in Table 3 .
Predictors of day seven atazanavir 24-h area under the concentration time curves
Dosing cohorts that satisfied protocol-defined pharmacokinetic criteria were used to examine predictors of ATV exposures. Age (r ¼ 0.15, P ¼ 0. 
Discussion
In this study of ATV pharmacokinetics administered without or with ritonavir, we identified doses for infants, children, and adolescents that met protocoldefined pharmacokinetic criteria. An unboosted ATV dose (capsule formulation) of 520 mg/m 2 met the study pharmacokinetic criteria for children aged more than 2 to 13 years or less and a dose of 620 mg/m 2 met the criteria for adolescents aged more than 13 to 21 years or less. A ritonavir-boosted ATV dose (powder formulation) of 310 mg/m 2 met the criteria for children aged more than 2 to 13 years or less and a dose (capsule formulation) of 205 mg/m 2 met the criteria for ages more than 2 to 21 years or less. A ritonavir-boosted ATV dose of 310 mg/m 2 (powder formulation) in children aged 3 months to 2 years achieved average ATV exposures that approximated, but did not meet protocol targets; there was greater variability in exposures among children in this age range. This study was unable to find an unboosted ATV dose with acceptable exposures in children aged 3 months to 13 years using ATV powder. Additional studies on the use of ATV powder are proceeding, using only ATV/r.
On average, ATV pharmacokinetics in the ritonavirboosted and unboosted dosing cohorts of IMPAACT P1020A that satisfied protocol-defined pharmacokinetic criteria approximated values for ATV in adults. Geometric mean (%CV) adult historic values for ATV AUC 0-24hr , C max , and C 24 following a ritonavir-boosted dose of 300 mg (176 mg/m 2 ) are 44.2 mg Â h/ml (34), 4427 ng/ml (28), and 709 ng/ml (60), respectively [12] . As illustrated in Fig. 1a , ATV C L/F is faster in infants and children less than 12 years of age relative to adults [10] . This could be due to a number of physiologic factors including, but not limited to, decreased bioavailability, increased drug transporter expression or activity, and/or greater hepatic enzyme capacity or function in younger children. Unboosted ATV C L/F appears similar for children aged 6-13 years with historical data in adults; C L/F is faster, however, in adolescents aged 13-22 years (Fig. 1b) . As noted, we were not able to find a dose of unboosted ATV powder that satisfied our pharmacokinetic parameters for children between 3 months to 13 years. This likely arose because of a combination of factors including low bioavailability, fast clearance, and wide intersubject variability in these pharmacokinetic characteristics.
Once a BSA-based dose was identified that satisfied protocol-defined pharmacokinetic criteria for the various age and formulation cohorts, day 7 (steady-state) ATV exposures were not predicted by or correlated with age, BSA, weight, formulation, and ritonavir boosting. There were also no racial or sex differences in exposures. However, there were significant differences in ATV exposures at day 7 between American and South African children. This difference was driven primarily by the two groups on unboosted ATV (group 3 and 4) and infants aged 3-6 months on ATV/r (group 5A). The South African children in these groups had faster BSAadjusted ATV C L/F than the American children ( Table 4 ). The reasons for faster C L/F in South African children are unclear. It may be a consequence of differences in type and amount of food consumed for the intensive pharmacokinetic visits (as meals were not standardized).
Helicobacter pylori is more prevalent in South African children relative to the United States, which may give rise to poorer ATV absorption because of a higher gastric pH in South African children [13] . Finally, genetic differences in drug metabolizing enzyme or transporter expression or function between American and South African children could provide an explanation.
The unboosted ATV capsule doses, which satisfied protocol-defined pharmacokinetic criteria in these children, are higher than the FDA-approved unboosted ATV dose for adults (520 and 620 mg/m 2 vs. 235 mg/m 2 ) and, in general, C max and C 24 were higher and lower, respectively, compared with ATV/r cohorts. The data from this study provided the basis for the FDA-approved ritonavir-boosted ATV dosing regimen in children aged 6-18 years. However, the FDA-recommended doses are based on body weight rather than BSA. The approved dose is also capped at the adult ritonavir-boosted dose, 300 mg once daily. There were 33 children aged 6-18 years in ritonavir-boosted dosing cohorts that passed our protocol-defined pharmacokinetic criteria (group 6, 7, and 8). We compared the starting doses of these 33 children in our study with the FDA-approved weightbased dose. Fourteen (42%) children would have received different starting doses of ATV when based on weight vs. BSA. Twelve of 14 children (86%) would have received a lower dose based on body weight than what they received in the study with the BSA-based dose. This may lead to differences in therapeutic outcomes in practice relative to those observed in this clinical trial.
There are limitations to this study that may impact generalizability. First, both abacavir and tenofovir disoproxil fumarate were excluded. ATV concentrations are reduced with concomitant tenofovir disoproxil fumarate administration; thus, if tenofovir disoproxil fumarate was coadministered with ATV (and ritonavir) in children, concentrations of ATV would be expected to be lower than that observed in this study [14] . Additionally, gastric acid modifiers were not exclusionary medications to participation in the study. However, only three children (all from the United States) were receiving gastric acid modifiers during the day 7 intensive pharmacokinetic visits. Two of these children were in group 5.
This study demonstrated once-daily BSA-determined doses using the capsule formulation of ATV, when given with and without ritonavir, can provide ATV exposures in children that approximate concentrations in adults receiving ATV/r. Once-daily unboosted ATV powder was unable to achieve protocol-defined pharmacokinetic targets. Although the powder formulation of ATV when given with ritonavir met protocol-defined pharmacokinetic criteria for children aged 2-13 years, there was significant variability in exposures in those less than 2 years of age, driven primarily by lower exposures in South African infants. Additional studies are needed in this age group to determine if an appropriate ritonavirboosted dose can be identified. Studies are also needed to elucidate the explanation for lower unboosted ATV exposures in South African children relative to American children. A manuscript describing the safety and efficacy of ATV and ATV/r in P1020A is forthcoming. An investigation of pharmacokinetic-dynamic relationships at the conclusion of the study may provide additional guidance for future studies of ATV dosing in children.
